1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / NIH. NIAID invites small business grant applications proposing to test and evaluate non-viral technologies capable of delivering RNA-based therapeutics into disease-relevant cells and tissues in vivo.
This includes specific sites of infection, such as the lung, relevant for the treatment of HIV-associated co-infections like tuberculosis. This NOSI leverages parent small business funding opportunities.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses. Applicants must submit through a parent small business notice of funding opportunity (NOFO) (PHS 2023 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications or PHS 2023 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications) or a subsequent version. Confirm the full requirements in the official notice before applying.
Applications for Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) is funded by National Institute of Allergy and Infectious Diseases (NIAID) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Collaborative Network for Clinical Research on Immune Tolerance is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / NIH. This program aims to enhance understanding of the underlying mechanisms of immune tolerance, and to develop improved tolerogenic interventions for the prevention and treatment of immune system mediated diseases, including transplant rejection, autoimmune diseases, and asthma and…
Notice of Special Interest (NOSI): Women's Health Research is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / NIH. This NOSI highlights NIAID's interest in applications focused on disease and health conditions that predominantly affect women, present and progress differently in women, or are female-specific. It aligns with the White House Initiative on Women's Health Research.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleNIAID's RFA-AI-28-024 funds preclinical malaria vaccines, from AI-guided design to cGMP lots, through a phased R61/R33. It allows one application per institution, bars foreign subawards, and excludes GLP tox.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article